Curr Opin Cardiol. 2011;26:232 6. 7.7.4. ICD Use After Heart Transplantation S7.7.4-1. Tsai VW, Cooper J, Garan H, et al. The efficacy of implantable car- dioverter-defibrillators in heart transplant recipients: results from a multicenter registry. Circ Heart Fail. 2009;2:197 201. S7.7.4-2. McDowell DL, Hauptman PJ. Implantable defibrillators and cardiac resynchronization therapy in heart transplant recipients: results of a national survey. J Heart Lung Transplant. 2009;28:847 50. S7.7.4-3. Neylon A, Canniffe C, Parlon B, et al. Implantable cardioverter-defi- brillators in a heart transplant population: A single-center experi- ence. J Heart Lung Transplant. 2016;35:682 4. S7.7.4-4. Vakil K, Taimeh Z, Sharma A, et al. Incidence, predictors, and tem- poral trends of sudden cardiac death after heart transplantation. Heart Rhythm. 2014;11:1684 90. S7.7.4-5. Vaseghi M, Lellouche N, Ritter H, et al. Mode and mechanisms of death after orthotopic heart transplantation. Heart Rhythm. 2009;6:503 9. 7.8. Neuromuscular Disorders S7.8-1. Bhakta D, Groh MR, Shen C, et al. Increased mortality with left ven- tricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1. Am Heart J. 2010;160:1137 41, 41. S7.8-2. Merino JL, Carmona JR, Fernandez-Lozano I, et al. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implica- tions for catheter ablation. Circulation. 1998;98:541 6. S7.8-3. Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter- defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492 8. S7.8-4. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59:493 500. S7.8-5. Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sud- den death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209 10. S7.8-6. Pasotti M, Klersy C, Pilotto A, et al. 